Your browser doesn't support javascript.
loading
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Rha, Sun Young; Oh, Do-Youn; Yañez, Patricio; Bai, Yuxian; Ryu, Min-Hee; Lee, Jeeyun; Rivera, Fernando; Alves, Gustavo Vasconcelos; Garrido, Marcelo; Shiu, Kai-Keen; Fernández, Manuel González; Li, Jin; Lowery, Maeve A; Çil, Timuçin; Cruz, Felipe Melo; Qin, Shukui; Luo, Suxia; Pan, Hongming; Wainberg, Zev A; Yin, Lina; Bordia, Sonal; Bhagia, Pooja; Wyrwicz, Lucjan S.
Afiliación
  • Rha SY; Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. Electronic address: rha7655@yuhs.ac.
  • Oh DY; Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
  • Yañez P; Department of Internal Medicine, James Lind Cancer Research Center, Universidad de La Frontera, Temuco, Chile.
  • Bai Y; Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Ryu MH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Lee J; Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea.
  • Rivera F; Department of Medical Oncology, University Hospital Marqués de Valdecilla, IDIVAL, Santander, Spain.
  • Alves GV; Centro Integrado de Pesquisa em Oncologia, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil.
  • Garrido M; Department of Hemato-Oncology, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Shiu KK; Gastrointestinal Oncology Service, University College London Hospitals, University College London Cancer Institute, NHS Foundation Trust, London, UK.
  • Fernández MG; Hemato Oncólogo, IMAT-Oncomedica, Montería, Colombia.
  • Li J; Department of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
  • Lowery MA; Department of Medical Oncology, Trinity St James Cancer Institute, Dublin, Ireland.
  • Çil T; Department of Medical Oncology, Health and Science University, Adana City Hospital, Adana, Turkey.
  • Cruz FM; Department of Medical Oncology, Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil.
  • Qin S; Department of Medical Oncology, Cancer Center of People's Liberation Army, Nanjing, China.
  • Luo S; Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China.
  • Pan H; Department of Medical Oncology, Zhejiang University School of Medicine, Sir Run Run Shaw Hospital, Hangzhou, China.
  • Wainberg ZA; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Yin L; Biostatistics and Research Decision Sciences, Merck, Rahway, NJ, USA.
  • Bordia S; Global Clinical Development, Merck, Rahway, NJ, USA.
  • Bhagia P; Global Clinical Development, Merck, Rahway, NJ, USA.
  • Wyrwicz LS; Department of Oncology and Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Lancet Oncol ; 24(11): 1181-1195, 2023 Nov.
Article en En | MEDLINE | ID: mdl-37875143
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Adenocarcinoma Límite: Female / Humans / Male Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Adenocarcinoma Límite: Female / Humans / Male Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article